Free Trial

Molecular Partners (MOLN) Stock Forecast & Price Target

Molecular Partners logo
$5.38 -0.13 (-2.36%)
(As of 11:36 AM ET)

Molecular Partners - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
1

Based on 2 Wall Street analysts who have issued ratings for Molecular Partners in the last 12 months, the stock has a consensus rating of "Buy." Out of the 2 analysts, 1 has given a hold rating, and 1 has given a strong buy rating for MOLN.

Consensus Price Target

$4.50
-16.36% Downside
According to the 2 analysts' twelve-month price targets for Molecular Partners, the average price target is $4.50. The highest price target for MOLN is $4.50, while the lowest price target for MOLN is $4.50. The average price target represents a forecasted downside of -16.36% from the current price of $5.38.
Get the Latest News and Ratings for MOLN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Molecular Partners and its competitors.

Sign Up

MOLN Analyst Ratings Over Time

TypeCurrent Forecast
11/15/23 to 11/14/24
1 Month Ago
10/16/23 to 10/15/24
3 Months Ago
8/17/23 to 8/16/24
1 Year Ago
11/15/22 to 11/15/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
N/A
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$4.50$4.50$4.50N/A
Forecasted Upside-16.36% Downside-9.09% Downside-30.02% DownsideN/A
Consensus Rating
Buy
Buy
Hold
N/A

MOLN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MOLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Molecular Partners Stock vs. The Competition

TypeMolecular PartnersMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside-16.36% Downside25,026.23% Upside8.16% Upside
News Sentiment Rating
Neutral News

See Recent MOLN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/7/2024Leerink Partnrs
5 of 5 stars
J. Chang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
12/5/2023JPMorgan Chase & Co.
3 of 5 stars
 Lower TargetNeutral ➝ Neutral$6.60 ➝ $4.50+1.12%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:59 AM ET.


MOLN Forecast - Frequently Asked Questions

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Molecular Partners is $4.50, with a high forecast of $4.50 and a low forecast of $4.50.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Partners in the last year. There is currently 1 hold rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MOLN shares.

According to analysts, Molecular Partners's stock has a predicted downside of -16.36% based on their 12-month stock forecasts.

Over the previous 90 days, Molecular Partners's stock had 1 upgrade by analysts.

Molecular Partners has been rated by research analysts at Leerink Partnrs in the past 90 days.

Analysts like Molecular Partners more than other "medical" companies. The consensus rating for Molecular Partners is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MOLN compares to other companies.


This page (NASDAQ:MOLN) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners